Exploring the FDA’s draft guidance on AI in regulatory decision-making

In January 2025, the Food and Drug Administration (FDA) issued long-awaited draft guidance on the use of artificial intelligence (AI) in regulatory decision-making for drugs and biological products. In this blog, the Boyds Regulatory Affairs team outlines the new guidance and its aims.